In Law360, Health Care Attorneys Examine Drug Pricing Reforms and Value-Based Pricing

In The News
August 3, 2020
Thomas N. Bulleit
Elana Bengualid Harary

In a Law360 article, health care partner Tom Bulleit (Washington, D.C.), and health care associate Elana Bengualid (New York) examine the current bevy of federal administrative and legislative proposals in the context of existing federal law governing drug prices, with the aim of identifying the future and current effects that such proposals may hold for the drug industry.

The article is the first in a series to examine how the current wave of drug pricing reforms may affect drug companies' business operations and, in particular, their compliance with existing federal price reporting and pricing requirements. The second article will address the implications of state drug pricing initiatives, and the third article will explore enforcement of federal pricing requirements.